Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1684187

registered interest
date	22/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask Secretary of State for Health and Social Care, what estimate she has made of the number of people with type 2 diabetes impacted by the GLP-1 shortage.
tabling member constituency	Darlington
tabling member printed	Peter Gibson
uin	10916
answer	answer is ministerial correction date of answer 29/01/2024 answer text <p>Information on the number of people impacted by the glucagon-like peptide 1 (GLP-1) shortage is not held by the Department. There continues to be a global supply issue with some GLP-1 receptor agonists, but following the Department’s ongoing engagement with manufacturers, NHS England, the Medicines and Healthcare products Regulatory Agency and others operating in the supply chain, the overall supply position has improved, with additional stock being secured to boost availability of these medicines for patients.</p><p>We issued updated guidance to healthcare professionals, in the form of a National Patient Safety Alert, on 3 January 2024. This provides advice on how to manage patients requiring these medicines. Our guidance remains clear that GLP-1 receptor agonists that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be prescribed for weight loss.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/01/2024 16:02:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4754 label Biography information for Peter Gibson

1658561

registered interest
date	06/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the availability of medicines for type-2 diabetes on the level of diagnoses of (a) diabetic foot disease and (b) other associated illnesses.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	198109
answer	answer is ministerial correction date of answer 12/09/2023 answer text <p>NHS England National Diabetes Audit core quarterly and annual dashboards will allow the assessment of changes in rates of complications over any periods of medicine shortages retrospectively, although attributing any such changes to any medicine shortages specifically to the level of diagnoses of diabetic foot disease and other associated illnesses is unlikely to be possible.</p> answering member constituency Colchester answering member printed Will Quince question first answered 12/09/2023 16:20:14 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1078461

registered interest
date	27/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the cost to the NHS of diabetes drugs prescriptions by CCG from 2018 to date.
tabling member constituency	Leicester East
tabling member printed	Keith Vaz
uin	226528
answer	answer is ministerial correction date of answer 07/03/2019 answer text <p>NHS Digital oversees the publication of ‘Prescribing for Diabetes’ which reports on and examines prescribing trends on medicines prescribed in primary care in England for the treatment and monitoring of diabetes. Data for the year 2018/19 will be published in November 2019 and the report for 2017/18 can be accessed at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/prescribing-for-diabetes" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/prescribing-for-diabetes</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/03/2019 16:21:04 answering member 4067 label Biography information for Steve Brine
tabling member	338 label Biography information for Keith Vaz

1667631

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of Ozempic pens for patients with type 2 diabetes.
tabling member constituency	Brentford and Isleworth
tabling member printed	Ruth Cadbury
uin	242
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>We are aware of a supply issue with glucagon-like peptide 1 receptor agonist (GLP-1 RA) medicines, including Ozempic pens. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 243 question first answered 17/11/2023 12:35:15 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4389 label Biography information for Ruth Cadbury

885335

registered interest
date	17/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of local NHS formularies in delivering best outcomes for people with diabetes.
tabling member constituency	Knowsley
tabling member printed	Mr George Howarth
uin	136198
answer	answer is ministerial correction date of answer 25/04/2018 answer text <p>NHS England has advised that it is not aware of any assessments nationally on the effectiveness of local National Health Service formularies in delivering best outcomes for people with diabetes.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/04/2018 16:11:43 answering member 4067 label Biography information for Steve Brine
tabling member	481 label Biography information for Sir George Howarth

823373

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with GPs and clinical bodies on improving the rate at which diabetics take their medications.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	122856
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The appropriate use of prescribed medication for diabetes, and any actions to support this, can form part of the annual reviews between general practitioners and their diabetes patients. NHS England is also overseeing the investment of diabetes transformation funding towards improved access to diabetes structured education within individual clinical commissioning groups.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:02:40 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1660994

registered interest
date	15/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with international counterparts on addressing shortages medicines to treat type 2 diabetes.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	199819
answer	answer is ministerial correction date of answer 21/09/2023 answer text <p>The Department has established processes to manage disruption to medical products and protect patient care. Supply chains for medical products are complex, global, and highly regulated, making them vulnerable to a variety of shocks, including around manufacture failure, demand spikes, international trade activity and disruption to logistics. In this specific case of medicines to treat type 2 diabetes, we are aware of a global supply issue with glucagon-like peptide-1 receptor agonists which are licensed for treating patients with type 2 diabetes. Whilst no specific discussions have been had with international counterparts, we are committed to working with international partners on the broader supply agenda.</p><p>We are continuing to work closely with manufacturers of medicines to treat type 2 diabetes and others working in the supply chain to help ensure the continued supply for patients in the United Kingdom, for example by asking suppliers to expedite deliveries. Alongside, we have provided advice for healthcare professionals on how to manage patients requiring these medicines whilst there are in shortage and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Colchester answering member printed Will Quince question first answered 21/09/2023 09:31:49 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1379295

registered interest
date	17/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the (a) Royal College of Nursing and (b) other relevant stakeholders on emerging drugs to treat diabetes.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	76694
answer	answer is ministerial correction date of answer 06/12/2021 answer text <p>The Department has had no specific discussions with the Royal College of Nursing or other stakeholders. There are well established drugs for the management of diabetes and we continue to engage with stakeholders on this issue. Driving research and innovation in diabetes care remains a key priority.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 06/12/2021 14:13:38 answering member 4492 label Biography information for Maria Caulfield
tabling member	4131 label Biography information for Jim Shannon

1660728

registered interest
date	14/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number and proportion of people with type 2 diabetes who will be affected by the shortage of GLP1-RA medications.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	199596
answer	answer is ministerial correction date of answer 19/09/2023 answer text <p>The information requested is currently not held centrally. The Department is monitoring demand for GLP1-RA medication using prescriptions data from the NHS Business Services Authority.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/09/2023 15:57:51 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1666738

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken mitigate the impact of shortages of (a) Ozempic, (b) Rybelsus, (c) Trulicity, (d) Victoza, (e) Saxenda, (f) Byetta and (g) Bydureon.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	203902
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of a supply issue with GLP-1 RA medicines. This includes Ozempic, Rybelsus, Trulicity, Victoza, Saxenda, Byetta and Bydureon. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine while there are shortages and are keeping this under review as the situation evolves.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:37:24 answering member 4423 label Biography information for Will Quince
tabling member	4603 label Biography information for Preet Kaur Gill